LLY

1,017.05

-2.37%↓

JNJ

244.37

+0.26%↑

ABBV

227.58

-2.48%↓

NVS

165.25

-0.83%↓

MRK

120.73

-0.93%↓

LLY

1,017.05

-2.37%↓

JNJ

244.37

+0.26%↑

ABBV

227.58

-2.48%↓

NVS

165.25

-0.83%↓

MRK

120.73

-0.93%↓

LLY

1,017.05

-2.37%↓

JNJ

244.37

+0.26%↑

ABBV

227.58

-2.48%↓

NVS

165.25

-0.83%↓

MRK

120.73

-0.93%↓

LLY

1,017.05

-2.37%↓

JNJ

244.37

+0.26%↑

ABBV

227.58

-2.48%↓

NVS

165.25

-0.83%↓

MRK

120.73

-0.93%↓

LLY

1,017.05

-2.37%↓

JNJ

244.37

+0.26%↑

ABBV

227.58

-2.48%↓

NVS

165.25

-0.83%↓

MRK

120.73

-0.93%↓

Search

Maravai LifeSciences Holdings Inc (Class A)

Ouvert

2.97 -0.34

Résumé

Variation du prix de l'action

24h

Actuel

Min

2.89

Max

3

Chiffres clés

By Trading Economics

Revenu

44M

-26M

Ventes

-5.8M

42M

Marge bénéficiaire

-61.388

Employés

550

EBITDA

44M

-22M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+52.03% upside

Dividendes

By Dow Jones

Prochains Résultats

25 févr. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

63M

1.1B

Ouverture précédente

3.31

Clôture précédente

2.97

Score Technique

By Trading Central

Confiance

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

17 févr. 2026, 23:44 UTC

Actions en Tendance

Stocks to Watch: La-Z-Boy, Palo Alto Networks, Caesars

17 févr. 2026, 23:20 UTC

Résultats

Palo Alto Networks Lifts FY26 Revenue Outlook as 2Q Profit Jumps -- Update

17 févr. 2026, 22:57 UTC

Résultats

Santos Fiscal Year Net Profit Falls 33%, Nears Start of Alaska Project

17 févr. 2026, 21:59 UTC

Résultats

Palo Alto Networks Lifts FY26 Revenue Outlook as 2Q Profit Jumps

17 févr. 2026, 23:54 UTC

Market Talk

Nikkei May Rise as Fears About AI Disruption Ease -- Market Talk

17 févr. 2026, 23:54 UTC

Market Talk

Global Equities Roundup: Market Talk

17 févr. 2026, 23:54 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 févr. 2026, 23:45 UTC

Market Talk

Suncorp's Outperformance of IAG Could Be Hard to Sustain -- Market Talk

17 févr. 2026, 23:19 UTC

Résultats

Palo Alto's Guidance Overshadows Strong Earnings. Its Stock Is Down. -- Barrons.com

17 févr. 2026, 23:15 UTC

Résultats

Palo Alto's Guidance Overshadows Strong Earnings. Its Stock Is Down. -- Barrons.com

17 févr. 2026, 22:58 UTC

Market Talk
Acquisitions, Fusions, Rachats

Netflix Would Operate Warner's Studios, HBO Largely the Same -- Market Talk

17 févr. 2026, 22:58 UTC

Acquisitions, Fusions, Rachats

BlueScope Steel: Board Committed to Optimizing Value For Shareholders

17 févr. 2026, 22:57 UTC

Acquisitions, Fusions, Rachats

BlueScope Steel to Consider Revised SGH, Steel Dynamics Takeover Bid

17 févr. 2026, 22:50 UTC

Acquisitions, Fusions, Rachats

Agnico-Eagle Mines Acquired 662,780 Common Shrs of Maple Gold Mines at C$2.45 Per Common Shr >AEM.T

17 févr. 2026, 22:44 UTC

Résultats

Palo Alto Reports Strong Earnings. Its Stock Is Down. -- Barrons.com

17 févr. 2026, 22:42 UTC

Résultats

Santos FY Net Profit Falls 33%, Nears Start of Alaska Project

17 févr. 2026, 22:36 UTC

Market Talk
Acquisitions, Fusions, Rachats

Netflix Sarandos: Paramount Causing Confusion Around Warner Deal -- Market Talk

17 févr. 2026, 22:36 UTC

Résultats

Santos Final Dividend 10.3 U.S. Cents/Security

17 févr. 2026, 22:36 UTC

Résultats

Santos FY Underlying Profit US$898 Million, Down 25%

17 févr. 2026, 22:35 UTC

Résultats

Santos FY Revenue US$4.94 Billion, Down 8%

17 févr. 2026, 22:35 UTC

Résultats

Correct: Santos FY Net Profit US$818 Million, Down 33%

17 févr. 2026, 22:35 UTC

Acquisitions, Fusions, Rachats

Berkshire Buys New York Times Stock; Sells Apple, Bank of America, Amazon In 4Q -- Barrons.com

17 févr. 2026, 22:34 UTC

Résultats

Santos FY Net Profit US$818 Billion, Down 33%

17 févr. 2026, 22:02 UTC

Acquisitions, Fusions, Rachats

Berkshire Pares Stakes in Apple and BofA, Adds New York Times Position -- Update

17 févr. 2026, 21:50 UTC

Acquisitions, Fusions, Rachats

Steel Dynamics: SGH Would Buy BlueScope, On-sell North American Operations to SDI, As Earlier Proposed

17 févr. 2026, 21:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Tech, Media & Telecom Roundup: Market Talk

17 févr. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17 févr. 2026, 21:49 UTC

Acquisitions, Fusions, Rachats

Steel Dynamics Says Revised Proposal Continues to Present Highly Strategic Opportunity For SDI Shareholders

17 févr. 2026, 21:48 UTC

Acquisitions, Fusions, Rachats

Steel Dynamics: BlueScope Offer a 56% Premium to 52-Week Volume Weighted Average Price

17 févr. 2026, 21:48 UTC

Acquisitions, Fusions, Rachats

Steel Dynamics: Consideration To Be Comprised Entirely of Cash

Comparaison

Variation de prix

Maravai LifeSciences Holdings Inc (Class A) prévision

Objectif de Prix

By TipRanks

52.03% hausse

Prévisions sur 12 Mois

Moyen 4.5 USD  52.03%

Haut 4.5 USD

Bas 4.5 USD

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

2 ratings

2

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

2.02 / 2.115Support & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

No Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat